European Commission Approves Actelion’s Uptravi for Pulmonary Arterial Hypertension Treatment
Actelion recently announced that the European Commission has granted marketing authorization for Uptravi (selexipag) for the treatment of patients with pulmonary arterial hypertension (PAH). Uptravi is a prostacyclin receptor agonist that leads to vasodilation in the pulmonary circulation. It has been proven effective in the treatment of subsets of patients…